Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval. Serious side effects reported with Merilog include hypoglycemia, severe allergic ...

The FDA approved 3 mL single-patient-use prefilled pen and 10 mL multiple-dose vial versions of the drug. Merilog is the first rapid-acting insulin biosimilar to be approved by the agency.

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.